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Objectives To identify differences and similarities in HbA1c levels and patterns regarding 
age and gender in eight high income countries. 
Subjects 66,071 children and adolescents below18 years of age with type 1 diabetes for at 
least 3 months and at least one HbA1c measurement during the study period. 
Methods Pediatric Diabetes Quality Registry data from Austria, Denmark, England, 
Germany, Norway, Sweden, US and Wales were collected between 2013 and 2014. HbA1c, 
gender, age and duration were used in the analysis. 
Results Distribution of gender and age groups was similar in the eight participating countries. 
The mean HbA1c varied from 60 to 73 mmol/mol (7.6 to 8.8%) between the countries. The 
increase in HbA1c between the youngest (0-9 years) to the oldest (15-17 years) age group was 
close to 8 mmol/mol (0.7%) in all countries (p<0.001). Females had a 1 mmol/mol (0.1%) 
higher mean HbA1c than boys (p<0.001) in seven out of eight countries. 
Conclusions In spite of large differences in the mean HbA1c between countries, a remarkable 
similarity in the increase of HbA1c from childhood to adolescence was found. 






Type 1 diabetes mellitus is one of the most common chronic diseases among children and 
adolescents and the incidence has increased during the last decades 1. It is well known that 
poor metabolic control, measured as HbA1c, increases the risk of  micro- and/or 
macrovascular complications 2. The Diabetes Control and Complication Trial (DCCT) 
showed that intensive therapy delays the onset of long-term complications and slows their 
progression 3. Several subsequent studies have confirmed that improved metabolic control in 
type 1 diabetes decreases the risk of complications 4,5. Furthermore, the type 1 diabetes 
population also has a higher mortality rate than the general population, and risk for mortality 
increases with poorer metabolic control 6.   
International Society for Pediatric and Adolescent Diabetes (ISPAD) and American Diabetes 
Association (ADA), suggested a target HbA1c of < 58 mmol/mol  (<7.5%) as the target for 
metabolic control in children and adolescents 7-9 at the time of the study, but national 
guidelines have since then argued for an even lower target value of 48 mmol/mol (6.5%) 10, 
referring to newer treatment regimens with reduction of risk for severe hypoglycemia. A high 
proportion of children and adolescents do not reach the treatment target, especially during 
adolescence 11,12. Furthermore, a gender-dependent difference in metabolic outcome has been 
described, with females showing poorer glycemic control both in childhood and during 
adolescence 13,14.  
With an aim to improve quality of care, track changes with time, and allow comparison 
between centers, several national diabetes registries have been established since the late 
1990s. Comparison of registry data between countries has generated continuous interest over 
the past years, and has identified differences between countries as well as among centers 




A recent study has demonstrated a considerable difference in mean HbA1c among, and 
variation across centers within eight high income countries 17,18 . To try to better understand 
this difference, the present study aimed to identify differences and similarities in HbA1c 
levels and patterns regarding age and gender in these countries. 
 
Methods 
Study Design and Participants   
The study design has been described in detail previously 17. To summarize, anonymized data 
from six registries/audits on children with type 1 diabetes, according to ISPAD guidelines, 
were used. The registries/audits represent eight western high-income countries: Sweden from 
the Swedish Pediatric Diabetes Quality Registry (SWEDIABKIDS), Denmark from the 
Danish National Diabetes Registry (DanDiabKids), Norway from the Norwegian Childhood 
Diabetes Registry (NCDR), England and Wales from the National Paediatric Diabetes Audit 
(NPDA), Germany and Austria from the Prospective Diabetes Follow-up Registry (DPV), and 
USA from the T1D Exchange (T1DX). Except for T1DX, which is a clinic-based registry, all 
other registries are population-based registries with coverage of more than 80% of the 
respective countries’ population of children with type 1 diabetes (table 1).  
 
There is slight discrepancy in study population compared to the study by Charalampopoulos 
et al 17 due to different inclusion criteria. In this study, the inclusion criteria were: age <18 
years, and type 1 diabetes for at least 3 months and at least one HbA1c measurement during 
the study period in 2013 (except in England and Wales where data were collected between 




available HbA1c value over the study period was used for each child. We excluded children 
with missing HbA1c values (N=4096 [6%]). The final sample consisted of 66,071 children 
with type 1 diabetes. 
All reported HbA1c values are in accordance with the International Federation of Clinical 
Chemistry (IFCC) 19 (mmol/mol). Corresponding HbA1c in National Glycohemoglobin 
Standardization Program (NGSP) units (%) are given in parenthesis. At the time of the study, 
nationally agreed target values for HbA1c were different between participating countries 
(Table 1).  
Actual age at last registered HbA1c was used. Age at onset was registered for all children and 
used for calculation of actual diabetes duration. The following groupings of age and diabetes 
duration were used: 0-9 years old, 10-14 years old and 15-17 years of age; < 2 years, 2-5 
years and > 5 years duration (Table 2). 
The study was approved by the individual registry/audits in each country with ethical 
approval to collect patient data. 
 
Statistical analysis 
The Mann-Whitney U test and the Kruskal-Wallis test were used for unadjusted comparisons 
of continuous variables between two and more than 2 groups, respectively. Categorical 
variables were analyzed by the Chi-square test. 
The Bonferroni-Holm method was applied to adjust p-values for multiple testing.  
HbA1c by year of age stratified by country was depicted by nonparametric local regression 
smoothing (LOESS). 
Multiple linear regression models were used to compare HbA1c levels between countries 




including the interaction between country and age group as covariate was implemented to 
compare differences in pubertal HbA1c increase between countries. Furthermore Holm-
Tukey`s method was used to account for multiple comparisons in regression models. All 
analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). 
Results 
This international benchmarking study includes registry data on HbA1c values from 66,071 
patients across eight high income countries. The sample size varied between countries from 
22,503 (England) to 1,376 patients (Wales) (Table 1). Missing data on HbA1c varied between 
0.2 % in Sweden and 16.8 % in the USA. Mean age at onset differed from 6.9 to 7.7 
(p<0.001) years and the mean diabetes duration ranged from 5.1 to 6.2 years (p<0.001). In the 
total population, the mean age at onset was 7.4 (± 3.9) and the mean diabetes duration 5.4 
years (± 3.8). There were slightly more males than females in all countries (Table 1). 
After adjustment for age, diabetes duration and gender, the mean HbA1c in the included 
countries showed a range of 60-73 mmol/mol (7.6-8.8%), (p<0.001) (Table 3). After 
adjustment for age and diabetes duration, the difference in HbA1c in males among most 
pairwise country comparisons (i.e. each country was compared with the other participating 
countries one by one) was significant (p<0.01). Exceptions (i.e. not significant) included 
Austria and Denmark vs. Germany, and England vs. USA. Among females, the HbA1c 
difference among most pairwise country comparisons (i.e. each country was compared with 
the other participating countries one by one) also was significant (p<0.01), with the 
exceptions (i.e. not significant) being Austria and Denmark vs. Germany, England vs. Wales, 
and USA vs. Wales, respectively. Females had a 1 mmol/mol (0.1%) higher mean HbA1c 
than males (p<0.001) in all countries except for Wales where no difference was seen in mean 
Hba1c.  After adjustment for diabetes duration and gender, an increase in HbA1c with 




countries were found in each of the three age groups. The difference in HbA1c between the 
youngest vs. the oldest age group was 8 mmol/mol (0.7%) in all countries except for Germany 
7 mmol/mol (0.6%) and Norway 9 mmol/mol (0.8%) (Table 3). The increase in HbA1c with 
increasing age in all countries is shown in Figure 1 using non-parametric regression of 
smoothing (LOESS).  The slope of the curve becomes steeper at approximately 8-10 years of 
age regardless of the country`s baseline HbA1c level at age 8. The increase in HbA1c from 
childhood to adolescence is significant in all countries (p<0.001).  
Discussion 
In the present study, we found that the effect of age and gender on HbA1c is remarkably 
similar across eight high income countries and independent of the mean HbA1c for the 
population. Specifically, we found that HbA1c was higher in older children with an increase 
of approximately 8 mmol/mol (0.7 %), being very similar across all countries and independent 
of the adjusted mean HbA1c. The difference of 1 mmol/mol in HbA1c rise between Germany, 
Norway and the rest of the countries is of no clinical significance although it probably would 
be statistically significant depending on the large number of patients in each registry. 
The differences in HbA1c between countries could not be explained by differences in age and 
gender. Regardless of the distribution of age groups and gender the differences in HbA1c 
between countries are the same. A somewhat unexpected finding was that the difference in 
mean HbA1c between males and females was minimal with a magnitude of no clinical 
importance.     
The reason for the higher HbA1c with increasing age has been described earlier in a 
multinational study 20, and the cause for this could be multifactorial. It could be due to 
biological and behavioral differences during adolescence 11,21, attitudes among caregivers and 




all equally important to improve care and should be taken into account together. For example, 
Sweden has the same increase in HbA1c with age as the other countries, in spite of showing a 
lower overall mean HbA1c after the development of a nationwide program of continuous 
quality improvement 23. In countries with a low HbA1c in younger age groups compared to 
others, the HbA1c in the oldest age group was correspondingly low. As the difference in 
HbA1c between countries was the same in all age groups, some factors seem to influence the 
overall care in all countries rather than being a result of a more effective treatment in a certain 
age group. It was striking that teenagers in Austria, Denmark, Germany and Sweden seemed 
to have the same HbA1c level as the youngest age groups, i.e. preschool children, in England, 
Wales and US. The well-known increase in HbA1c during adolescence 12 seems to be the 
same in all countries.  
Other groups have published longitudinal HbA1c data by age.  In Scotland, a report from 
2001 found a similar age pattern: HbA1c levels were significantly higher in older children 
(age 10-15 years 80 mmol/mol (9.5%) vs. other ages 73 mmol/mol (8.8%), P < 0.001) 26. 
Clements et al has shown the same pattern from longitudinal data for T1D Exchange 27. 
However, Mochizuki et al did not find lower HbA1c in the younger age group in Japan 28. 
Since the difference in HbA1c existed over all age groups, national targets of HbA1c could 
have influenced the results. Sweden had the lowest target, and also the lowest HbA1c in all 
age groups. National targets thus seem to be important for the mean national HbA1c. 
Lowering targets may be one way to improve pediatric diabetes care 29. USA lowered their 
target to < 58 mmol/mol (<7.5%) in 2014, England and Wales to <48 mmol/mol (<6.5%) in 
2015 and Sweden to <48 mmol/mol (<6.5%) in 2017. ISPAD has lowered the target to <53 
mmol/mol (<7.0%) in 2018 30. Future follow-up of national HbA1c comparisons will show if 




increase of 8 mmol/mol (0.7%) during adolescence seems to be independent of national 
targets and mean HbA1c. 
Apart from national targets, there may be differences in the approach to treatment in the 
different countries and also different approaches to technology such as pumps, number of 
injections per day, continuous glucose monitors etc. National improvement programs like the 
program in Sweden 31 and national tariffs in England 32 can be expected to further improve the 
outcome. 
Our study should be interpreted within the context of its limitations. We do not have data on 
insulin regimes, socioeconomic status or comorbidity and therefore we do not know whether 
it could explain some of the observed variation. We also do not have data on severe 
hypoglycemia or episodes of DKA. The European registries are population-based while data 
from the US, although being the largest pediatric type 1 diabetes dataset available in the US, 
was based on a selective group of diabetes clinics12. The proportion of patients with short 
duration of diabetes is very low in the US T1D Exchange registry, which could explain some 
of the HbA1c differences observed between that registry and those of other countries. Another 
limitation is that the dataset originates several years back. However, recent data from the US 
indicate a rise in HbA1c in all pediatric age groups 33, while it has gone down in the UK 34.  
 
In conclusion, we found a remarkable similarity in the increase of HbA1c from childhood to 
adolescence in spite of large differences in the mean HbA1c between countries. Variation in 
national targets for HbA1c may have contributed to this difference. It seems important to 
develop multidisciplinary diabetes care teams that set a low HbA1c target during childhood 
and adolescence. International benchmarking projects are essential in highlighting similarities 
and differences in the treatment of children and adolescents with type 1 diabetes and give the 




contributing to the observed differences between countries, such as the impact of HbA1c 
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Austria 1597 1583 7.3 (4.0) 5.1 (3.7) 45 53 (7.0) ~80% 
Denmark 2074 1894 7..7 (3.9) 5.1 (3.6) 49 55 (7.2) ~100% 
England 22503 21401 7.6 (4.0) 5.3 (3.7) 48 58 (7.5) >95% 
Germany 20580 20187 7.4 (3.9) 5.2 (3.7) 48 58 (7.5) ~95% 
Norway 2416 2321 7.5 (3.8) 5.2 (3.5) 48 <58 (<7.5) >95% 
Sweden 6540 6524 7.4 (4.0) 5.5 (3.8) 47 52 (6.9 ) ~98% 
USA 13081 10877 6.9 (3.7) 6.2 (3.4) 48 < 6 years 69 
(8.5 ) 
6-12 years 64 
(8.0) 
> 13 years 58 
(7.5 ) 
N/A 
Wales 1376 1284 7.5 (3.9) 5.2 (3.6) 48 58 (7.5) >95% 
Total 70167 66071 7.4 (3.9) 5.4 (3.8) 48   
 
Table 1. Data on the number of patients, the number of patients with HbA1c, age at onset, diabetes 
duration and proportion of females from the eight participating registries, target value for HbA1c for 

























<2 years 24 20 21 23 20 21 5 22 
2-
<5years 
31 36 33 32 34 31 39 32 
>=5 
years 
45 44 46 45 46 48 56 46 
 
Table 2. The proportion of patients in the groups stratified by diabetes duration < 2 years, 2-5 years 





Country mean -HbA1c mmol/mol and  % (95% CI)  















































































































































Table 3. Linear regression models (pooled model) Total and age group HbA1c data are adjusted for 
age, duration and gender. Gender HbA1c data are adjusted for age and duration. a-g describe non-
significant differences in HbA1c between countries with the same letter. 
 
 
 
 
